MedTrace Logo

Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological Immunotherapie

NCT06031233 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 776

Last updated 2026-03-30

No results posted yet for this study

Summary

This study is an interventional, explorative, prospective study to show whether shortening of infusion times for patients using nivolumab, pembrolizumab, ipilimumab, trastuzumab, bevacizumab, durvalumab or atezolizumab continues to be associated with an acceptable safety profile.

Infusion times will be gradually shortened if tolerability allowes.

Conditions

Interventions

DRUG

Nivolumab

Gradual shortening of infusion times

DRUG

Pembrolizumab

Gradual shortening of infusion times

DRUG

Ipilimumab

Gradual shortening of infusion times

DRUG

Durvalumab

Gradual shortening of infusion times

DRUG

Atezolizumab

Gradual shortening of infusion times

DRUG

Bevacizumab

Gradual shortening of infusion times

DRUG

Trastuzumab

Gradual shortening of infusion times

DRUG

Rituximab

Gradual shortening of infusion times

Sponsors & Collaborators

  • Isala

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-09-01
Primary Completion
2028-07-31
Completion
2028-12-31

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06031233 on ClinicalTrials.gov